Precigen, Inc. (PGEN) Stock Analysis

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

Fri, October 30, 2026 at 10:24 PM UTC 2 min read

PGEN's stock plummeted 27% in after-hours trading following the announcement that rival Inovio's rare disease drug received FDA approval. This development is significant for investors as it highlights increased competition in the biotech sector, potentially impacting PGEN's market position and future revenue prospects. The sharp decline reflects investor concerns over PGEN's ability to maintain its competitive edge amidst advancements by competitors.

Read full article →

Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis

Mon, October 12, 2026 at 3:38 PM UTC 2 min read

Precigen (PGEN) has successfully launched its commercial product, validating its early capital raise strategy. This achievement underscores the company's potential for revenue generation and growth, which is crucial for investors assessing its long-term viability. The successful launch not only reinforces investor confidence but also positions Precigen favorably in the competitive biotech landscape.

Read full article →